Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Total Liabilities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Total Liabilities for 7 consecutive years, with $43.9 million as the latest value for Q3 2024.

  • On a quarterly basis, Total Liabilities fell 3.21% to $43.9 million in Q3 2024 year-over-year; TTM through Sep 2024 was $43.9 million, a 3.21% decrease, with the full-year FY2023 number at $45.1 million, down 5.54% from a year prior.
  • Total Liabilities was $43.9 million for Q3 2024 at Actinium Pharmaceuticals, down from $46.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $47.7 million in Q4 2022 to a low of $4.0 million in Q2 2021.
  • A 4-year average of $31.8 million and a median of $44.5 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 1002.88% in 2022, then dropped 5.54% in 2023.
  • Actinium Pharmaceuticals' Total Liabilities stood at $6.8 million in 2021, then soared by 597.22% to $47.7 million in 2022, then decreased by 5.54% to $45.1 million in 2023, then decreased by 2.57% to $43.9 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Total Liabilities are $43.9 million (Q3 2024), $46.0 million (Q2 2024), and $44.5 million (Q1 2024).